Trump’s Drug Pricing Order Could Boost Indian Pharma by $2.25 Billion

President Donald Trump’s recent executive order aiming to lower U.S. prescription drug prices could significantly benefit India’s pharmaceutical sector. The order, which seeks to reduce drug costs by tying them to prices in economically comparable countries, may inadvertently open doors for Indian drugmakers to expand their footprint in the U.S. market.

India, supplying nearly 50% of generic drugs in the U.S., stands to gain from this policy shift. The U.S. accounts for about 30% of India’s pharmaceutical exports, translating to billions in revenue. Companies like Sun Pharma, Dr. Reddy’s, and Cipla could see increased demand as the U.S. looks for cost-effective drug sources.

However, the proposed 25% tariff on pharmaceutical imports poses a challenge. While intended to encourage domestic manufacturing, such tariffs could impact the profitability of Indian exporters. Industry leaders argue that the U.S. lacks the capacity to quickly replace these imports, suggesting that Indian generics will remain essential in the short term.

Analysts believe that, despite potential short-term disruptions, the long-term outlook for Indian pharma in the U.S. remains positive. The combination of cost advantages and established supply chains positions India to play a pivotal role in the U.S. healthcare landscape.